Skip to main content
. 2007 Oct 30;97(11):1538–1544. doi: 10.1038/sj.bjc.6604044

Figure 1.

Figure 1

GnT-V and β1–6 branching glycoprotein expression, and β1–6GlcNAc branching of β1 integrin in endometrial cancer tissues. (A) Western blot analysis with anti-GnT-V mAb. (B) Lectin blot analysis with L4-PHA. Lanes 1–7 corresponded to seven different endometrial cancer patients (G1, grade 1; G2, grade 2; G3, grade 3). P, JAR is a choriocarcinoma cell line used as a positive control for GnT-V expression; N, normal human uterine smooth muscle cells (UtSMC) as a negative control. (C) β1 integrin was immunoprecipitated from endometrial cancer tissues from three different patients. The amount of β1–6GlcNAc branching of β1 integrin was analysed by means of an L4-PHA lectin blot (upper panel). The membrane was reprobed with a specific mAb to β1 integrin (lower panel).